| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 150, 1165-1172, Copyright © 1997 by American Society for Investigative Pathology
REGULAR ARTICLES |
J Yuan, A Horlin, B Hock, HJ Stutte, H Rubsamen-Waigmann and K Strebhardt
Chemotherapeutisches Forschungsinstitut, Georg-Speyer-Haus, Frankfurt, Germany.
PLK (polo-like kinase) belongs to a family of serine/threonine kinases and represents the human counterpart of polo in Drosophila melanogaster and of CDC5 in Saccharomyces cerevisiae. It is strongly involved in spindle formation and chromosome segregation during mitosis. We have shown previously that PLK mRNA expression correlates with the mitotic activity of cells and the prognosis of lung cancer patients. In this report, the level of PLK protein was analyzed using immunohistochemical techniques. PLK protein was found expressed in the nuclei of tumor cells from lung and breast cancer as well as in several tumor cell lines. Furthermore, in peripheral lymphocytes treated with phytohemagglutinin, elevated proliferative activity of the cells correlated with the up-regulation of PLK protein expression. In contrast, in U937 and HL-60 cells after induction of differentiation with phorbol ester, PLK immunostaining disappeared under conditions of terminal differentiation. Most of the PLK protein was found in the nucleus of proliferating cells with diffuse but distinct staining also in the cytoplasm. Taken together, high levels of PLK protein are associated with cellular proliferation. Combined with other proliferative and oncogene markers, PLK may be useful for improved prediction of the clinical prognosis of cancer patients and for early cancer diagnosis. Due to its activity late in the cell cycle, it may be a target for cancer chemotherapy.
This article has been cited by other articles:
 |
|
 |
|
  S. Kappel, Y. Matthess, B. Zimmer, M. Kaufmann, and K. Strebhardt Tumor inhibition by genomically integrated inducible RNAi-cassettes Nucleic Acids Res., September 11, 2006; 34(16): 4527 - 4536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Garland, C. Taylor, D. L. Pilkington, J. L. Cohen, and D. D. Von Hoff A Phase I Pharmacokinetic Study of HMN-214, a Novel Oral Stilbene Derivative with Polo-Like Kinase-1-Interacting Properties, in Patients with Advanced Solid Tumors Clin. Cancer Res., September 1, 2006; 12(17): 5182 - 5189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Eckerdt, J. Yuan, K. Saxena, B. Martin, S. Kappel, C. Lindenau, A. Kramer, S. Naumann, S. Daum, G. Fischer, et al. Polo-like Kinase 1-mediated Phosphorylation Stabilizes Pin1 by Inhibiting Its Ubiquitination in Human Cells J. Biol. Chem., November 4, 2005; 280(44): 36575 - 36583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Gunawardena, H. Siddiqui, D. A. Solomon, C. N. Mayhew, J. Held, S. P. Angus, and E. S. Knudsen Hierarchical Requirement of SWI/SNF in Retinoblastoma Tumor Suppressor-mediated Repression of Plk1 J. Biol. Chem., July 9, 2004; 279(28): 29278 - 29285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ando, T. Ozaki, H. Yamamoto, K. Furuya, M. Hosoda, S. Hayashi, M. Fukuzawa, and A. Nakagawara Polo-like Kinase 1 (Plk1) Inhibits p53 Function by Physical Interaction and Phosphorylation J. Biol. Chem., June 11, 2004; 279(24): 25549 - 25561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Spankuch, Y. Matthess, R. Knecht, B. Zimmer, M. Kaufmann, and K. Strebhardt Cancer Inhibition in Nude Mice After Systemic Application of U6 Promoter-Driven Short Hairpin RNAs Against PLK1 J Natl Cancer Inst, June 2, 2004; 96(11): 862 - 872. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Gray Jr, D. J. Bearss, H. Han, R. Nagle, M.-S. Tsao, N. Dean, and D. D. Von Hoff Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer Mol. Cancer Ther., May 1, 2004; 3(5): 641 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Larsson, C. Scheele, Z. Liang, J. Moll, C. Karlsson, and C. Wahlestedt Kinetics of Senescence-associated Changes of Gene Expression in an Epithelial, Temperature-sensitive SV40 Large T Antigen Model Cancer Res., January 15, 2004; 64(2): 482 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. AHMAD Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer FASEB J, January 1, 2004; 18(1): 5 - 7. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Spankuch-Schmitt, J. Bereiter-Hahn, M. Kaufmann, and K. Strebhardt Effect of RNA Silencing of Polo-Like Kinase-1 (PLK1) on Apoptosis and Spindle Formation in Human Cancer Cells J Natl Cancer Inst, December 18, 2002; 94(24): 1863 - 1877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Yuan, A. Kramer, F. Eckerdt, M. Kaufmann, and K. Strebhardt Efficient Internalization of the Polo-Box of Polo-like Kinase 1 Fused to an Antennapedia Peptide Results in Inhibition of Cancer Cell Proliferation Cancer Res., August 1, 2002; 62(15): 4186 - 4190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Macmillan, J. W. Hudson, S. Bull, J. W. Dennis, and C. J. Swallow Comparative Expression of the Mitotic Regulators SAK and PLK in Colorectal Cancer Ann. Surg. Oncol., October 1, 2001; 8(9): 729 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Strebhardt,, L. Kneisel, C. Linhart, A. Bernd, and R. Kaufmann Prognostic Value of Pololike Kinase Expression in Melanomas JAMA, January 26, 2000; 283(4): 479 - 480. [Full Text] [PDF]
|
|
|
|
|
|
R. Knecht, R. Elez, M. Oechler, C. Solbach, C. v. Ilberg, and K. Strebhardt Prognostic Significance of Polo-like Kinase (PLK) Expression in Squamous Cell Carcinomas of the Head and Neck Cancer Res., June 1, 1999; 59(12): 2794 - 2797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kimura, Y. Matsuda, T. Yoshioka, and Y. Okano Cell Cycle-dependent Expression and Centrosome Localization of a Third Human Aurora/Ipl1-related Protein Kinase, AIK3 J. Biol. Chem., March 12, 1999; 274(11): 7334 - 7340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Glover, I. M. Hagan, and A. A.M. Tavares Polo-like kinases: a team that plays throughout mitosis Genes & Dev., December 15, 1998; 12(24): 3777 - 3787. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
